Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 9/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528767 | 0.85 | RAB9A (0.47) | CYP2C9FAAHMEN1ALDH1A1HPGD | |
| SCHEMBL4534870 | 0.81 | KDR (0.47) | CYP3A4MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL14650182 | 0.80 | MAP4K4 (0.54) | FAAHMEN1ALDH1A1KMT2AMAP4K4 | |
| SCHEMBL4534098 | 0.79 | RAB9A (0.44) | HSD17B1HSD17B2CYP2C9FAAHMEN1 | |
| SCHEMBL4537136 | 0.79 | MEN1 (0.56) | CYP3A4CYP2C9MEN1ALDH1A1HPGD | |
| SCHEMBL4530786 | 0.79 | RAB9A (0.41) | FAAHMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL4539780 | 0.78 | MAP4K4 (0.49) | FAAHKMT2AMAP4K4VCP | |
| SCHEMBL13963164 | 0.77 | FLT1 (0.49) | FAAHMAP4K4ADORA1PIK3CA | |
| SCHEMBL4532640 | 0.77 | RXRA (0.40) | HSD17B1HSD17B2MEN1ALDH1A1KMT2A | |
| SCHEMBL4524356 | 0.77 | ADORA2A (0.46) | PARP1ALDH1A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | HSD17B1 1277/4885HSD17B2 965/4885CYP3A4 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.